Evidence map›Paper›PMID 32103088›Full record

ArticleScientific reports2020

Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants.

Naho Ichikawa, Giuseppe Lisi, Noriaki Yahata, Go Okada, Masahiro Takamura, Ryu-Ichiro Hashimoto, Takashi Yamada, Makiko Yamada, Tetsuya Suhara, Sho Moriguchi and 10 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 2 countries.

Naho IchikawaDepartment of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Giuseppe LisiATR Brain Information Communication Research Laboratory Group, Kyoto, Japan.
Noriaki YahataInstitute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Go OkadaDepartment of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Masahiro TakamuraDepartment of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Ryu-Ichiro HashimotoMedical Institute of Developmental Disabilities Research, Showa University, Tokyo, Japan.
Takashi YamadaATR Brain Information Communication Research Laboratory Group, Kyoto, Japan.
Makiko YamadaInstitute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Tetsuya SuharaInstitute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Sho MoriguchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masaru MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Yujiro YoshiharaDepartment of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hidehiko TakahashiDepartment of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kiyoto KasaiDepartment of Youth Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobumasa KatoMedical Institute of Developmental Disabilities Research, Showa University, Tokyo, Japan.
Shigeto YamawakiDepartment of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Ben SeymourATR Brain Information Communication Research Laboratory Group, Kyoto, Japan. ben@atr.jp.
Mitsuo KawatoATR Brain Information Communication Research Laboratory Group, Kyoto, Japan.
Jun MorimotoATR Brain Information Communication Research Laboratory Group, Kyoto, Japan.
Yasumasa OkamotoDepartment of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. oy@hiroshima-u.ac.jp.
Hiroshima University · JPResearch Organization of Information and Systems · JPNational Institutes for Quantum and Radiological Science and Technology · JPKeio University · JPShowa University · JPKyoto University · JPThe University of Tokyo · JPTokyo Medical and Dental University · JPUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limited efficacy of available antidepressant therapies may be due to how they affect the underlying brain network. The purpose of this study was to develop a melancholic MDD biomarker to identify critically important functional connections (FCs), and explore their association to treatments. Resting state fMRI data of 130 individuals (65 melancholic major depressive disorder (MDD) patients, 65 healthy controls) were included to build a melancholic MDD classifier, and 10 FCs were selected by our sparse machine learning algorithm. This biomarker generalized to a drug-free independent cohort of melancholic MDD, and did not generalize to other MDD subtypes or other psychiatric disorders. Moreover, we found that antidepressants had a heterogeneous effect on the identified FCs of 25 melancholic MDDs. In particular, it did impact the FC between left dorsolateral prefrontal cortex (DLPFC)/inferior frontal gyrus (IFG) and posterior cingulate cortex (PCC)/precuneus, ranked as the second 'most important' FC based on the biomarker weights, whilst other eight FCs were normalized. Given that left DLPFC has been proposed as an explicit target of depression treatments, this suggest that the limited efficacy of antidepressants might be compensated by combining therapies with targeted treatment as an optimized approach in the future.

Identifiers

PMID32103088
PMCPMC7044159
OpenAlexW3007352445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.